Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

August 30, 2015 6:53 PM ET


Company Overview of Opus Bio, Inc.

Company Overview

Opus Bio, Inc. develops and commercializes lentiviral gene delivery products for human diseases for therapeutic, vaccine, and bioproduction applications. The company’s product pipeline includes treatment for chronic lymphocytic leukemia, glioblastoma, melanoma, and hemophilia A; vaccine preclinical programs and vaccine candidates, including virus like particles vaccines that target pandemic and seasonal influenza, Hepatitis C virus infection, and HIV/AIDS; and protein therapeutics that include the production of erythropoietin and factor VIII. It also has various programs on various stem cell types, such as hematopoietic (or blood making) stem cells (HSC) for the treatment of cancer and chron...

910 Clopper Road

Suite 200 South

Gaithersburg, MD 20878

United States

Founded in 2004





Key Executives for Opus Bio, Inc.

Chief Executive Officer and Director
Vice President of Vector Development
Director of Business Planning
Director of Research & Development
Director of Quality Control
Compensation as of Fiscal Year 2015.

Opus Bio, Inc. Key Developments

Juno Therapeutics Partners with Opus Bio

Juno Therapeutics, Inc. entered into an agreement to obtain a license from Opus Bio, Inc. (formerly Lentigen Corporation) for a CAR-T cell product candidate targeting CD22, a protein expressed on most B cell leukemias and lymphomas. Both the companies are based in the US.

Lentigen Corporation Presents at Lazard Capital Markets' GenomeRX: Genes as Drugs Workshop & 1x1 Access Day, Oct-01-2013

Lentigen Corporation Presents at Lazard Capital Markets' GenomeRX: Genes as Drugs Workshop & 1x1 Access Day, Oct-01-2013 . Venue: New York, New York, United States.

Similar Private Companies By Industry

Company Name Region
Interpace Diagnostics, LLC United States
SouthernBiotech United States
LifeGen Technologies LLC United States
Cortexyme, Inc. United States
Blue Angel Holdings Corporation United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Opus Bio, Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at